

Supplementary material 1.**Vaccine immunogenicity according to brand.**

Vaccine brand	BNT162b2	mRNA -1273	p value
Cohort 1	N= 52	N= 48	
Seroconversion	28 (53%)	27 (56%)	0.72
IgG anti-spike levels	210±290	220±320	0.65
CD4 T-cell response	25 (48%)	27 (56%)	0.28
CD8 T-cell response	26 (50%)	27 (56%)	0.38
Cohort 2	N= 32	N=18	
Seroconversion	23 (72%)	15 (83%)	0.37
IgG anti-spike levels	425±2320	460±2830	0.67
CD4 T-cell response	23 (72%)	12 (80%)	0.70
CD8 T-cell response	23 (72%)	13 (87%)	0.28
Cohort 3	N=29	N=21	
Seroconversion	27 (100%)	23 (100%)	
IgG anti-spike levels	512± 2123	584±1997	0.68
CD4 T-cell response	29 (100%)	21 (100%)	
CD8 T-cell response	26 (89%)	20 (95%)	0.76